Aug 18, 2016 09:20
7 yrs ago
English term
Croatia
Translation you can trust
Native in: Belarusian 
, Russian
Works in: English to Russian, English to Belarusian, Russian to Belarusian, and 10 more.
patients with R/M
English to Russian
Medical
Medical (general)
chemotherapies are used for patients with R/M
R/M first line patients have heterogeneous characteristics
R/M first line patients have heterogeneous characteristics
Proposed translations
(Russian)
| 3 +4 | пациенты с рецидивом или метастазами |
Evgeni Kushch
|
| 5 | рецидивным и/или метастатическим плоскоклеточным раком |
Larisa Horback
|
Proposed translations
+4
3 mins
Evgeni Kushch
Ukraine
Ukraine
Native in Russian
Specializes in field
Ukraine
MD with 12+ years in medical translation
Native in: Russian (Variant: Standard-Russia) , Ukrainian (Variant: Standard-Ukraine)
Works in: English to Russian, English to Ukrainian, Russian to English, and 3 more.
Related KudoZ points
:
895
Selected
пациенты с рецидивом или метастазами
Предположу из ограниченного контекста:
A few patients with a locoregional recurrence can be salvaged by surgery or reirradiation. However, most patients with recurrent or metastatic (R/M) disease only qualify for palliative treatment.
http://annonc.oxfordjournals.org/content/21/suppl_7/vii252.l...
--------------------------------------------------
Note added at 5 mins (2016-08-18 09:26:16 GMT)
--------------------------------------------------
Patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) receiving platinum-based chemotherapy as their first-line treatment have a dismal prognosis, with a median overall survival (OS) of ~7 months.
http://www.ncbi.nlm.nih.gov/pubmed/24973959
Recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is a devastating malignancy with a poor prognosis. Treatment is limited to chemotherapeutic approaches. Cisplatin is an established and effective treatment for R/M HNSCC, and many studies have investigated cisplatin treatment in combination with other agents. Even when being treated with first line therapy (cisplatin + 5-fluorouracil + cetuximab), overall survival is only 10 months, indicating the need for novel chemotherapeutics and treatment regimens. Current research is focused on molecular targeting therapies inhibiting epidermal growth factor receptor, phosphoinositide-3-kinase/Akt/mammalian target of rapamycin, and vascular endothelial growth factor pathways. A variety of clinical trials have been completed and are currently underway with encouraging results. Finally, future directions of cisplatin-based R/M HNSCC treatment may include targeting specific pathways known to induce cisplatin resistance, such as nucleotide excision repair and inhibition of apoptosis, in hopes to enhance response to cisplatin therapy.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3835153/
--------------------------------------------------
Note added at 6 mins (2016-08-18 09:26:59 GMT)
--------------------------------------------------
пациенты с рецидивом или метастазами [такого-то новообразования]
--------------------------------------------------
Note added at 4 hrs (2016-08-18 13:34:06 GMT)
--------------------------------------------------
пациенты с рецидивом/метастазами [такого-то новообразования]
A few patients with a locoregional recurrence can be salvaged by surgery or reirradiation. However, most patients with recurrent or metastatic (R/M) disease only qualify for palliative treatment.
http://annonc.oxfordjournals.org/content/21/suppl_7/vii252.l...
--------------------------------------------------
Note added at 5 mins (2016-08-18 09:26:16 GMT)
--------------------------------------------------
Patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) receiving platinum-based chemotherapy as their first-line treatment have a dismal prognosis, with a median overall survival (OS) of ~7 months.
http://www.ncbi.nlm.nih.gov/pubmed/24973959
Recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is a devastating malignancy with a poor prognosis. Treatment is limited to chemotherapeutic approaches. Cisplatin is an established and effective treatment for R/M HNSCC, and many studies have investigated cisplatin treatment in combination with other agents. Even when being treated with first line therapy (cisplatin + 5-fluorouracil + cetuximab), overall survival is only 10 months, indicating the need for novel chemotherapeutics and treatment regimens. Current research is focused on molecular targeting therapies inhibiting epidermal growth factor receptor, phosphoinositide-3-kinase/Akt/mammalian target of rapamycin, and vascular endothelial growth factor pathways. A variety of clinical trials have been completed and are currently underway with encouraging results. Finally, future directions of cisplatin-based R/M HNSCC treatment may include targeting specific pathways known to induce cisplatin resistance, such as nucleotide excision repair and inhibition of apoptosis, in hopes to enhance response to cisplatin therapy.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3835153/
--------------------------------------------------
Note added at 6 mins (2016-08-18 09:26:59 GMT)
--------------------------------------------------
пациенты с рецидивом или метастазами [такого-то новообразования]
--------------------------------------------------
Note added at 4 hrs (2016-08-18 13:34:06 GMT)
--------------------------------------------------
пациенты с рецидивом/метастазами [такого-то новообразования]
4 KudoZ points awarded for this answer.
5 hrs
Larisa Horback
United States
United States
Native in Russian
Works in field
United States
Simultaneous/Conference/Consecutive int
Native in: Russian (Variant: Standard-Russia) , Ukrainian (Variant: Standard-Ukraine)
Works in: Russian to English, Ukrainian to English, English to Russian, and 1 more.
рецидивным и/или метастатическим плоскоклеточным раком
The role of cetuximab maintenance after chemotherapy in patients with recurrent/metastatic squamous cell carcinoma of head and neck (R/M SCCHN).
Reference:
Note from asker:
| Спасибо! |
Peer comment(s):
| neutral |
Maksym Nevzorov
: будьте аккуратнее: не факт, что в контексте аскера речь идет именно о _плоскоклеточном раке_
4 hrs
|
|
из всех видов рака, карцинома или плоскоклеточный рак является самым распространенным раком(90%). Даже если это не карцинома метастазы поражают squamous cells,плоские клетки. Хотя каждый решает для себя, что верно, а что нет.
|
|
| neutral |
Evgeni Kushch
: Лариса, вы не могли бы уточнить, что вы имеете в виду фразой "метастазы поражают squamous cells, плоские клетки"?/О том, что метастазы поражают клетки плоского эпителия, я в линках не вижу. И так не пойму при чем здесь плоские клетки
5 hrs
|
|
Я привела линки, там все есть. В Ваших это тоже есть кстати. Удивительно, но у нас одни и теже ссылки.
|
Something went wrong...